Pablo Cagnoni is president and chief executive officer of Rubius Therapeutics. Over the course of Pablo’s career as an oncologist and pharmaceutical executive, he has been committed to advancing the development of breakthrough treatments for people with cancer and other diseases. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor®, Kyprolis® and Tarceva®.
Before joining Rubius in 2018, Pablo served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion. Prior to Tizona, he served as President of Onyx Pharmaceuticals (acquired by Amgen), where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).
Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Pablo earned his medical degree from University of Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
He is a member of the Board of Directors for Fusion Pharmaceuticals, Laronde, Repertoire Immune Medicines, Synthekine and the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization (BIO). He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics and was Executive Chairman of Blade Therapeutics.
Dannielle Appelhans joined Rubius as Chief Operating Officer in August of 2021, bringing experience in gene therapy, strategy, manufacturing, supply chain and operations. As COO, she oversees corporate strategy, communications, technical development, technical operations and quality for Rubius.
Dannielle joined from Novartis Gene Therapies, where she served as Senior Vice President of Technical Operations and Chief Technical Officer, and oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio. Before that role, she served as Senior Vice President, Global Head of Supply Chain Management for Novartis and was responsible for end-to-end supply chain of all Novartis divisions worldwide, across 60-plus plants in more than 120 countries to ensure $50 billion in sales. Since 2014, Dannielle held positions of increasing responsibility in global supply chain, strategy and operational excellence across several divisions within Novartis. Before joining Novartis, Dannielle was a senior engagement manager at McKinsey & Company, working in the pharmaceutical operations practice. Earlier in her career she held roles of increasing responsibility at Eli Lilly and Company.
Dannielle is a member of the Board of Directors for Generation Bio.
She has an MBA from MIT Sloan School of Management, a Master of Science from Massachusetts Institute of Technology and a Bachelor of Science from the University of Michigan in mechanical engineering.
Pepe joined Rubius Therapeutics as Chief Financial Officer since September 2020. Pepe previously served as the Chief Financial Officer of Radius Health, a biopharmaceutical company developing and commercializing endocrine therapeutics. At Radius Health, he was responsible for all financial aspects of the business as well as investor relations, business development and other operational functions. Under Pepe’s leadership, Radius Health was transformed from a clinical-stage company to a fully commercial organization. Pepe was instrumental in financing the company’s commercialization and pipeline investments, executing several business development transactions and building the finance organization, processes and systems. Prior to joining Radius, Pepe was Chief Financial Officer of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, Pepe held numerous financial management positions with increasing responsibilities at Novartis AG, in various divisions, as chief financial officer in Europe, North America, Latin America and held other senior global financial roles.
Pepe is a member of the Board of Directors for Senda Biosciences and Hotspot Therapeutics.
He received his B.S. in Industrial Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.
Spencer Fisk is the Chief Technical Operations Officer of Rubius and brings more than 25 years of experience in Manufacturing and CMC product development. Prior to joining Rubius, Spencer served as VP & Global Head of Cell & Gene Technical Development and Manufacturing at Novartis where he led the CMC development and manufacturing organization to deliver the CAR-T portfolio. Under his leadership, the team successfully registered and launched the first CAR-T cellular therapy product, Kymriah, which has demonstrated transformative efficacy in patients with acute lymphoblastic leukemia. While at Novartis, Spencer also led the process development teams in support of the commercialization of Cosentyx® and the registration and approval of ErelziTM and Rixathon®. Prior to Novartis, he led manufacturing and CMC functions in support of Somavert®, Elonva®, Retavase® and Puregon® while at Merck, formerly Schering Plough, Organon and Covance. Prior to Merck, Spencer held various process development and manufacturing roles at Genentech, Genencor and Novo Nordisk.
James “Jim” Jogerst joined Rubius as Chief Business Officer in August of 2021, bringing more than 20 years of experience in developing, structuring and closing high-level deals, including mergers and acquisitions, business development and licensing transactions. As CBO, he leads business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius’ overall corporate strategy.
Jim joins Rubius most recently from Janssen Pharmaceuticals, where he led licensing transactions in the company’s Infectious Diseases and Vaccines business. Before that, Jim spent nearly ten years at Alcon, Inc., where he developed and executed business development and licensing and mergers and acquisitions strategy for Alcon’s three global franchises: surgical, pharmaceutical and vision care. Earlier in his career Jim held executive positions in several investment banking boutiques in Dallas after starting his career in consulting with Arthur Andersen.
Jim has an MBA in Finance and International Business from Pepperdine University and a BA in Economics and Political Science from the University of North Texas. He also holds the Chartered Financial Analyst (“CFA”) designation.
Maiken Keson-Brookes joined Rubius as Chief Legal Officer and Corporate Secretary in November 2019, bringing more than 20 years of international legal experience and working biopharmaceutical companies from the discovery phase all the way through commercialization. She oversees Rubius’ legal and securities matters and intellectual property. Maiken joined Rubius from Synlogic, Inc., where she served as general counsel. Prior to Synlogic, she served as senior vice president and general counsel at uniQure, a gene therapy company. Before uniQure, she was senior vice president and general counsel at Forum Pharmaceuticals, where she established the company’s first legal department and built a legal team to support all aspects of the business. Earlier, Maiken held legal roles at Genzyme and Biogen. While with Biogen, she served as attorney for the ex-U.S. launch of several products and provided legal oversight for the company’s manufacturing group, including a large-scale manufacturing facility construction project.
Maiken holds master of laws and bachelor of laws degrees from Kings College University of London.
Jill Murray joined Rubius in 2019 as an HR Business Partner. She was promoted to Sr. Director, HR Business Partner and Head of Total Rewards in 2021 and now serves as Vice President and Head of Human Resources. Jill brings nearly 20 years of Human Resources experience across biotech and high-tech industries. Prior to her role at Rubius, she was Director of Organizational Development and a Human Resources Business Partner at Sarepta Therapeutics. Before that, Jill spent 13 years at ImmunoGen, Inc. holding numerous roles with increasing responsibilities in Human Resources. Earlier in her career, Jill held Human Resources roles in the high-tech industry.
Jill holds a Graduate Certificate in Human Resources Management from Capella University and a B.H.A from Carnegie Mellon University.
Lori Murray joined Rubius in 2018, and serves as the Chief Corporate Affairs Officer, leading internal and external communications, patient advocacy and corporate social responsibility. Prior to her role at Rubius, she was the Head of Corporate Affairs at Onyx Pharmaceuticals (acquired by Amgen), where she served on the leadership team and oversaw internal and external communications, global patient advocacy and provided investor relations support to Amgen for Onyx Pharmaceuticals.
Earlier in her career, she held corporate, product and marketing communications positions at WeissComm Partners, now W2O Group, a healthcare communications agency, Applied Biosystems, now Thermo Fischer Scientific, and ReGen Biologics, now Stryker. She began her career working on political campaigns in her home state of California.
Lori holds an MBA from the University of San Francisco and a B.A. in Rhetoric and Communications from the University of California, Davis.
Tamyra Toole joined Rubius in June 2018. She brings to Rubius more than 20 years of regulatory affairs and quality assurance experience in the biotechnology and pharmaceutical industry.
Prior to joining Rubius, she served as an independent regulatory affairs consultant to biotechnology companies. Prior to her role as a consultant, Tamyra was the Vice President of Regulatory Affairs and Quality Assurance at Infinity Pharmaceuticals, where she built the regulatory and quality teams and was responsible for the global regulatory strategy and the company’s compliance with quality regulations and standards. Previously, Tamyra held positions in regulatory affairs and quality assurance at NitroMed, Wyeth Pharmaceuticals, Millennium Pharmaceuticals and Organogenesis, Inc. She has experience in the development of drugs, biologics and early cell therapies across multiple therapeutic areas. Prior to working in drug development, Tamyra held various positions in the Department of Nursing at Brigham and Women’s Hospital.
Tamyra holds a B.S. in nursing from Villanova University and a J.D. from the Catholic University of America.
Laurence Turka, M.D., joined Rubius in January 2020 and serves as Chief Scientific Officer and Head of Research & Translational Medicine. Larry is an internationally recognized, physician-scientist in autoimmunity and translational immunology with a distinguished career working in academia and, more recently, industry.
Larry joined Rubius from Rheos Medicines, where he was a co-founder and served as Chief Scientific Officer. During his time at Rheos, he built its portfolio of novel therapies targeting the metabolism of immune cells, made key leadership hires, and was instrumental in securing a strategic collaboration between Rheos and Roche. Prior to Rheos, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he played a leading role in the creation of Rheos and provided immunology expertise in evaluating multiple company-building opportunities. Before joining venture capital, Larry spent 30 years working in academia, most recently serving as the Harold and Ellen Danser Professor of Surgery and Professor of Medicine at Harvard Medical School and Massachusetts General Hospital.
Among the notable discoveries of Larry’s laboratory were novel approaches to transplantation tolerance, the role of Toll-like receptors in T cells and pathways required for the maintenance of regulatory T cell function. Larry was also an early leader in the field of T cell costimulation and contributed to the development of abatacept and belatacept for the treatment of rheumatoid arthritis and renal transplantation.
He is a former President of the American Society of Transplantation, Chair of the NIAID Board of Scientific Counselors and Editor in Chief of The Journal of Clinical Investigation. He is currently the Deputy Director of the Immune Tolerance Network, serves on the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy and is the Harold and Ellen Danser Professor of Surgery (part-time) at Harvard Medical School. He was elected to membership in the American Society for Clinical Investigation in 1995, and the Association of American Physicians in 2003.
Larry received his M.D. from the Yale University School of Medicine, trained in internal medicine at Yale-New Haven Hospital and in nephrology at the Brigham and Women’s Hospital/Harvard Medical School.